Reply

Arthritis Care and Research

Volumn 66, Issue 10, 2014, Pages 1593-1596

  Bredemeier, Markus ^a  

^a HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ATTRIBUTABLE RISK; CLINICAL OBSERVATION; CLINICAL TRIAL (TOPIC); DAS28; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXTERNAL VALIDITY; FUNCTIONAL STATUS; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNAL VALIDITY; JOINT CAVITY; LABORATORY TEST; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WRIST; ARTHRITIS, RHEUMATOID; FEMALE; MALE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE;

EID: 84908502199     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22382     Document Type: Letter

References (12)

1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
2. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46.
3. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
4. Mariette X, Rouanet S, Sibilia J, Combe B, Le Loet X, Tebib J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis 2014;73:1508-14.
5. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 2010;49:1683-93.
6. Guillemin F. Primer: the fallacy of subgroup analysis. Nat Clin Pract Rheumatol 2007;3:407-13.
7. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35.
8. Peterfy C, Emery P, Tak P, Ostergaard M, DiCarlo J, Otsa K, et al. Rituximab (RTX) plus methotrexate (MTX) prevents bone erosion and joint-space narrowing (JSN) and reduces synovitis, osteitis as shown on MRI: results from a randomised, placebo-controlled trial in patients (pts) with rheumatoid arthritis (RA-SCORE) [abstract]. Ann Rheum Dis 2011;70 Suppl:152.
9. Roche Pharmaceuticals. A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab in the inhibition of joint structural damage assessed by magnetic resonance imaging in patients with rheumatoid arthritis and inadequate response to methotrexate (protocol number: MA21056). Clinical trial result informa-tion. Basel: Hoffmann-La Roche; 2011. URL: http://www.roche-trials.com/studyResultGet.action?studyResultNumber-MA21056.
10. Besada E, Nossent JC. Infection risks during long-term rituximab therapy change over time. J Rheumatol 2013;40: 203.
11. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 2012;71: 351-7.
12. Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum 2011;63:603-8.